Re: For those new: COVID-19 prophylactic/therapeutic...and tilmanocept -"CD206.... co-register with infectious SARS-CoV-2...The likelihood that macrophages are the instigator of the cytokine storm in liver as well as lung, is high."
Should be seeing Granted Patent Published soon..hopefully Navidea added
The following message was updated on 3/26/2022 6:50:48 PM.
Another agent they were developing was a therapeutic for COVID, CT-RX-I/I-001TL
October 2020) Physis received a follow-up data assessment regarding the
potential therapeutic efficacy of Covid-19 therapeutic agent
CT-RX-I/I-0001TL: Physis has received a second prospective data set
evaluating the potential of its anti-Covid-19 agent in Covid-19-infected
human tissues derived from deceased infected patients. The data
further indicate that 0001TL has a strong potential to provide
significant relief from Covid-19 -induced symptoms even in later stages
of the infection. The data, again, suggest that cell types other than
those expressing ACE2-r may be involved in infection and/or disease
progression. Physis is completing a third round of evaluations in a
large patient population tissue sample.
(15 December 2020 &
12 January 2021) Physis receives positive test results affecting the
potential development of its Covid-19 therapeutic agent CT-RX-I/I-001TL.
Physis has received data evaluations from human tissue samples from
Covid-19+ that further suggest that its agent would provide significant
benefit to SARs-Cov-2-infection. These data cover pulmonary, liver and
GI assessments. Physis is pursuing the IP and development of this
(01 January 2022 /01 July 2021) Physis receives
USPTO review of Covid-19 therapeutic agent CT-RX-I/I-0001TL - Physis
submits final IP package to USPTO for an anti-Covid agent. Physis
submits final patent documents (CT-RX-I/I-001TL) to the USPTO for use in
treating Covid 19 disease. This patent is based on Physis' data derived
from cadaver tissue assessments. Physis has received a review from the
USPTO and is completing its reply for final claims for the product.
Physis presented these data at the annual AAPS forum in Philadelphia on
19 October 2021 in an open forum for AAPS attendees. Physis received a
positive review of these data.
I finally found the AAPS abstract,
and the therapeutic is surprisingly enough uses tilmanocept as a
prophylactic and therapeutic to fight against the cytokine storm in the
lungs that results from COVID-19.
(W7110V) Pulmonary Macrophages as a Prophylactic/Therapeutic Target for Covid 19: Striking at the CD206 Receptor
1.CD206, CD163 and CD11b all co-register with infectious SARS-CoV-2; 2.
Substantially fewer viral elements are present in the alveolar
endothelial cells; 3. Macrophages are the overwhelming cytotype in the
deep lung that are targeted by the late stage CV19 disease; 4. The
likelihood that macrophages are the instigator of the cytokine storm and
Covid progression is high; 5. Modulation of these macrophages in Phases
2-4 (DAMP) with the absence of DISP factors may truly establish a
TARGETED therapeutic rescue by modulation of these macrophage states; 6.
The use of the targeted approach with tilmanocept may eliminate a virus
tolerization and replication state, resulting in the elimination of the
massive trans-alveolar migration/recruitment of monocytes that drive a
populating process which adds significantly to the alveolar macrophage
population, further exacerbating the clinical symptomology and driving
the patient to a DISP clinical state; 7. The likelihood that macrophages
are the instigator of the cytokine storm in liver as well as lung, is
like Cope et. al. are developing an additional patent for treatment of
Covid based on the Compounds and Methods for Diagnosis and Treatment of
Viral Infections patent he developed while at Navidea. Good to hear of
another therapeutic based on tilmanocept being developed that has been
publicly presented along with the cancer therapeutic that Navidea is
Original Message (# 36717)by ddin on 3/26/2022 6:49:05 PM